SCHEDULE 13G: Cantor Fitzgerald Discloses 5.2% Stake in OnKure Therapeutics

Cantor Fitzgerald and its affiliates have reported a 5.2% beneficial ownership stake in OnKure Therapeutics Inc., totaling 669,539 shares of Class A Common Stock.

Summary

• Cantor Fitzgerald Securities, Cantor Fitzgerald & Co., Cantor Fitzgerald, L.P., and CF Group Management, Inc. (collectively, the "Reporting Persons") have filed a Schedule 13G.
• The filing reports beneficial ownership of 669,539 shares of Class A Common Stock in OnKure Therapeutics Inc.
• This represents 5.2% of OnKure Therapeutics Inc.'s outstanding Class A Common Stock, based on 12,823,872 shares outstanding as of May 5, 2025.
• The filing also details a pending internal control transfer within the Cantor Fitzgerald group, where Howard W. Lutnick is divesting his voting shares of CF Group Management, Inc. to trusts controlled by Brandon G. Lutnick.
• This divestiture by Howard W. Lutnick is to comply with U.S. government ethics rules due to his appointment as the U.S. Secretary of Commerce.
• The control transfer is subject to customary closing conditions, including required regulatory approvals.

Sentiment

Score: 5

Explanation: The filing is a factual disclosure of beneficial ownership and an internal corporate governance change within the reporting group, not directly related to the issuer's operational performance. The sentiment is neutral as it primarily serves a compliance function.

Positives

• NA

Negatives

• NA

Risks

• The closing of the internal control transfer within the Cantor Fitzgerald group is subject to the satisfaction of customary closing conditions, including receipt of required regulatory approvals. Failure to obtain these approvals could delay or prevent the transfer.

Future Outlook

The filing indicates a future change in control within the Cantor Fitzgerald group, with Brandon G. Lutnick expected to gain voting or dispositive power over the Common Stock held by CFGM, pending regulatory approvals. This is a direct consequence of Howard W. Lutnick's impending appointment as the U.S. Secretary of Commerce.

Management Comments

• Each of the undersigned hereby acknowledges and agrees, in compliance with the provisions of Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, that the Schedule 13G to which this Agreement is attached as an Exhibit, and any amendments thereto, will be filed with the Securities and Exchange Commission jointly on behalf of the undersigned.
• By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.

Industry Context

This filing is a standard disclosure required when an entity acquires beneficial ownership of more than 5% of a class of a company's voting securities. It provides transparency regarding significant institutional holdings, which is crucial for market participants to understand ownership structures and potential influence. The internal restructuring within Cantor Fitzgerald due to a government appointment highlights the compliance requirements for individuals transitioning between private sector leadership and public service.

Comparison to Industry Standards

• This Schedule 13G filing adheres to the standard regulatory requirements for disclosing beneficial ownership exceeding 5%.
• Such disclosures are common among institutional investors like Cantor Fitzgerald, which frequently hold significant stakes in various public companies.
• The filing's primary purpose is compliance and transparency regarding ownership, not a performance assessment, and therefore does not provide specific comparable companies or projects for direct results assessment.

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• Howard W. Lutnick, in his capacity as trustee of a trust, entered into agreements to sell voting shares of CF Group Management, Inc. to trusts controlled by Brandon G. Lutnick. This is a transaction between related parties within the broader Cantor Fitzgerald group.

Stakeholder Impact

• Shareholders of OnKure Therapeutics Inc.: Provides transparency regarding a significant institutional ownership stake (5.2%), which can influence market perception and trading activity.
• Internal Stakeholders of Cantor Fitzgerald Group: The internal control transfer impacts the leadership and governance structure of the reporting entities, particularly CF Group Management, Inc., Cantor Fitzgerald, L.P., Cantor Fitzgerald Securities, and Cantor Fitzgerald & Co.
• Regulatory Authorities: The filing demonstrates compliance with SEC disclosure requirements for beneficial ownership and highlights the ethical considerations for individuals entering public service.

Next Steps

• Completion of the internal control transfer within the Cantor Fitzgerald group, subject to regulatory approvals.

Key Dates

Keywords

OnKure Therapeutics, Cantor Fitzgerald, Schedule 13G, Beneficial Ownership, Class A Common Stock, SEC Filing, Institutional Investor, Howard W. Lutnick, Brandon G. Lutnick, Secretary of Commerce